Company Filing History:
Years Active: 2020
Title: The Innovative Contributions of Daniel S. Green
Introduction
Daniel S. Green is a notable inventor based in Silver Spring, MD, who has made significant contributions to the field of cancer treatment. His work focuses on innovative methods and compositions aimed at improving therapeutic outcomes for patients suffering from ovarian cancer. With a single patent to his name, Green's research has the potential to impact the lives of many.
Latest Patents
Daniel S. Green holds a patent titled "Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer." This patent discloses methods and compositions for treating subjects with cancer, particularly those whose cancer cells express the interleukin 4 receptor (IL-4R). The compositions may include a chimeric molecule that binds to IL-4R, along with interferon alpha (IFNα) and interferon gamma (IFNγ). In certain embodiments, the compositions can also incorporate monocytes, enhancing the therapeutic efficacy of the treatment.
Career Highlights
Green is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His role at this prestigious institution allows him to engage in cutting-edge research and collaborate with other experts in the field. His work is characterized by a commitment to advancing cancer treatment methodologies.
Collaborations
Throughout his career, Daniel S. Green has collaborated with esteemed colleagues, including Raj K. Puri and Kathryn C. Zoon. These partnerships have fostered an environment of innovation and have contributed to the development of effective cancer therapies.
Conclusion
Daniel S. Green's contributions to cancer treatment through his innovative patent demonstrate his dedication to improving patient outcomes. His work at the National Institutes of Health and collaborations with other experts highlight the importance of teamwork in advancing medical research. The potential impact of his inventions on the treatment of ovarian cancer is significant and underscores the value of continued innovation in the field.